8.1 Pharmacoepidemiology, Population-Based Care, and Public Health

Pharmacoepidemiology, Population-Based Care, and Public Health

Quick Answer: Pharmacoepidemiology studies how drugs are used and what effects they produce in large populations, drawing on claims data, EHRs, and active surveillance systems such as FDA's Sentinel. Public health organizes prevention into three levels — primary, secondary, and tertiary — and frames practice around the social determinants of health and national goals set by Healthy People 2030.

Pharmacoepidemiology Foundations

Pharmacoepidemiology is the application of epidemiologic methods to study drug use and outcomes in defined populations. It sits at the intersection of clinical pharmacology and epidemiology, answering questions that premarketing trials cannot — rare adverse events, long-term effects, real-world effectiveness, and patterns of use in subpopulations. Whereas a randomized controlled trial establishes whether a drug can work under ideal conditions, pharmacoepidemiology studies describe whether it does work in practice.

Data Sources

Pharmacoepidemiologists rely on several data infrastructure types:

• Claims databases — insurance billing records (Medicaid, Medicare Part D, commercial claims) that capture dispensing events and diagnoses but lack clinical detail.
• Electronic health records (EHRs) — clinical data including labs, vitals, and notes, often richer but harder to standardize across systems.
• Disease registries — organized cohorts (e.g., SEER cancer registry, transplant registries) that follow patients longitudinally.
• FDA FAERS (FDA Adverse Event Reporting System) — spontaneous postmarket reports; useful for signal detection but subject to underreporting and reporting bias.
• FDA Sentinel Initiative — an active surveillance distributed network that queries electronic healthcare data in near real-time to monitor FDA-regulated medical products.
• FDA MAUDE — Manufacturer and User Facility Device Experience database for medical device adverse events.

Epidemiological Study Designs

Descriptive studies (case reports, case series, cross-sectional surveys) characterize frequency and patterns. Analytical studies test hypotheses by comparing groups.

Measures of Association

• Relative risk (RR) — incidence in exposed divided by incidence in unexposed; used in cohort studies.
• Odds ratio (OR) — odds of exposure in cases divided by odds of exposure in controls; used in case-control studies; approximates RR when the disease is rare (rare disease assumption).
• Attributable risk — excess incidence in the exposed group attributable to the exposure.
• Number needed to treat (NNT) — 1 divided by absolute risk reduction; the average number of patients who must be treated to prevent one additional event.

Population-Based Care and Prevention

Public health frames intervention as three prevention levels operating at the population scale.

Primary Prevention

Acts before disease occurs. Examples include immunizations, safe water and food supply, tobacco cessation counseling, motor-vehicle safety standards, and formulary guardrails that prevent high-risk prescribing.

Secondary Prevention

Detects and treats disease early to halt progression. Examples include blood pressure and lipid screening, cancer screening (mammography, colonoscopy), medication therapy management (MTM) reviews that identify untreated indications, and prescription drug monitoring program (PDMP) queries that detect misuse early.

Tertiary Prevention

Reduces complications of established disease. Examples include diabetic foot exams, anticoagulation clinics that prevent stroke in atrial fibrillation, cardiac rehabilitation, and opioid use disorder treatment with buprenorphine to reduce overdose mortality.

Infection Control and Antimicrobial Stewardship

Healthcare-associated infections remain a leading cause of preventable harm. Hand hygiene (WHO's "My 5 Moments") is the single highest-impact intervention. Isolation precautions — standard, contact, droplet, and airborne — match transmission routes. Antimicrobial stewardship programs (required for CDC recognition and CMS participation) optimize antibiotic selection, dose, and duration, slowing resistance and reducing C. difficile infections. Core stewardship elements include antibiotic timeouts, prior authorization for restricted agents, and prospective audit with feedback.

Social Determinants of Health (SDOH)

Healthy People 2030 organizes SDOH into five domains:

1. Economic stability — income, debt, housing costs.
2. Education access and quality — literacy, numeracy, higher education attainment.
3. Health care access and quality — insurance coverage, provider availability, cultural competence.
4. Neighborhood and built environment — safe housing, transportation, food access.
5. Social and community context — social support, discrimination, civic participation.

Pharmacists influence SDOH by addressing medication affordability, screening for low health literacy, and connecting patients to community resources.

Population Health Management

Pharmacies increasingly participate in value-based contracts that require risk stratification — segmenting patients into low, rising, and high-risk tiers — and care coordination across providers, payers, and community services. Pharmacist-led services such as MTM, comprehensive medication reviews (CMR), and chronic care management close gaps in care, reduce hospital readmissions, and align pharmacy metrics with payer Star Ratings.

Public Health Surveillance and Reporting

Pharmacists are mandated reporters for many conditions. Notifiable diseases — including HIV, tuberculosis, syphilis, measles, and COVID-19 — must be reported to state public health departments per jurisdiction-specific timelines. Vaccine adverse events are reported to the Vaccine Adverse Event Reporting System (VAERS). The Healthy People 2030 framework sets decade-long, measurable national objectives; leading health indicators include drug overdose deaths, vaccination rates, and access to comprehensive medication management.